financetom
CMPS
financetom
/
Healthcare
/
CMPS
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
COMPASS Pathways plcCMPS
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
256.24M
Revenue (ttm)
n/a
Net Income (ttm)
-155.12M
Shares Out
92.67M
EPS (ttm)
-2.30
PE Ratio
n/a
Forward PE
n/a
Dividend
n/a
Ex-Dividend Date
n/a
Volume
176,372
Open
2.710
Previous Close
2.700
Day's Range
2.665 - 2.775
52-Week Range
2.490 - 9.630
Beta
2.35
Analysts
Strong Buy
Price Target
20.20 (+630.56%)
Earnings Date
May 7, 2025
Description >

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States.

It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Copyright 2023-2025 - www.financetom.com All Rights Reserved